Navigation Links
PAREXEL International To Present At NASDAQ OMX Investor Conference
Date:6/19/2012

BOSTON, June 19, 2012 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL) announced today that it will be presenting at the NASDAQ OMX Investor Conference in London.  James Winschel, Sr. Vice President and Chief Financial Officer will be making a presentation on PAREXEL at 2:45 p.m.  BST on Tuesday, June 26, 2012.

A live webcast of the presentation will be available through the "Investors" section of PAREXEL's website at www.PAREXEL.com in the Upcoming Events portion of the main page, and a replay of the presentation will be available on the website until September 26, 2012.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.  Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process.  Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 50 countries around the world, and has approximately 11,920 employees. For more information about PAREXEL International visit www.PAREXEL.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contact:
Jill Baker, Corporate Vice President, Investor Relations
PAREXEL International
Tel: +781-434-4118
Email: Jill.Baker@PAREXEL.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
2. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
3. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
4. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
5. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
6. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
7. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
8. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
9. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
10. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
11. Chindex International, Inc. to Report First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
(Date:7/27/2017)... July 27, 2017  West Pharmaceutical Services, Inc. (NYSE: ... for the second-quarter 2017 and updated financial guidance for ... Second-Quarter 2017 Highlights Reported net sales ... the prior-year quarter. Net sales at constant currency (organic) ... EPS was $0.51, compared to $0.60 in the prior-year ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
Breaking Medicine Technology:
(Date:8/20/2017)... Centennial, CO (PRWEB) , ... August 20, 2017 , ... ... in the same household? If so, you may be interested in participating in ... The purpose of this research is to understand more about the relational aspects of ...
(Date:8/19/2017)... York, New York (PRWEB) , ... August 19, ... ... Street Health has announced that it is the first organization with pending recognition ... CDC’s National Diabetes Prevention Program (“DPP”) via group telehealth classes and live video ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners ... Orlando location as an interventional pain management physician. He brings a wealth of ... of migraine headaches, and significant experience in spinal cord stimulation for chronic pain. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
Breaking Medicine News(10 mins):